I am a
Home I AM A Search Login

Papers of the Week

Papers: 10 Aug 2019 - 16 Aug 2019

Human Studies

2020 Jan

Eur J Neurol



Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH Study.


Hartung H-P, Mallick R, Bril V, Lewis RA, Sobue G, Lawo J-P, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN
Eur J Neurol. 2020 Jan; 27(1):196-203.
PMID: 31400231.


Chronic inflammatory demyelinating polyneuropathy (CIDP) causes weakness which adversely impacts function and quality of life (QOL). CIDP often requires long-term management with intravenous or subcutaneous immunoglobulin. The Polyneuropathy and Treatment with Hizentra (PATH) study showed subcutaneous immunoglobulin (SCIG) was efficacious in CIDP maintenance. Here, we assess patient-reported outcomes in patients on SCIG.